Pacific Biosciences
PACB
160 hedge funds and large institutions have $873M invested in Pacific Biosciences in 2019 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 65 increasing their positions, 41 reducing their positions, and 23 closing their positions.
59% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 41
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
26% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 23
8% more capital invested
Capital invested by funds: $809M → $873M (+$63.2M)
6.85% more ownership
Funds ownership: 73.1% → 79.95% (+6.9%)
3% more funds holding
Funds holding: 155 → 160 (+5)
73% less call options, than puts
Call options by funds: $1.19M | Put options by funds: $4.36M
Top Buyers
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$22.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$19M |
| 3 |
KLCMU
Kite Lake Capital Management (UK)
London,
United Kingdom
|
+$18.7M |
| 4 |
WIC
Water Island Capital
New York
|
+$16.3M |
| 5 |
VI
Versor Investments
New York
|
+$15.2M |
Top Sellers
PACB Hedge Fund Activity: Q1 2019 in Review
160 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2019, worth a combined $873M — up 7.8% from $809M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new PACB positions and 23 closed out — a net gain of 6 holders — while 65 added to existing stakes and 41 trimmed.
The largest buyer was UBS O'Connor, adding an estimated $22.2M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $18.2M sold.
- 160 institutional investors held Pacific Biosciences (PACB) as of Q1 2019, up from 155 in Q4 2018.
- Funds reported $873M of Pacific Biosciences stock for Q1 2019, up 7.8% quarter-over-quarter.
- 29 funds opened new Pacific Biosciences positions in Q1 2019 and 23 closed out, a net change of +6 holders.
- The largest Pacific Biosciences buyer in Q1 2019 was UBS O'Connor, an estimated $22.2M added.
- The largest Pacific Biosciences seller in Q1 2019 was Consonance Capital Management, an estimated $18.2M sold.
Based on aggregated 13F filings for Q1 2019.